Novoheart Holdings

Name

Novoheart Holdings

Legal name

Novoheart Holdings Limited

Website

https://novoheart.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Stem Cell Bioengineering

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

akta.pro secondary industries

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA)

Keywords

• Stem cell bioengineering
• Cardiac drug discovery
• Cardiotoxicity screening
• Disease modeling services
• Preclinical research services

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. mini-Heart Products: Sale of do-it-yourself kits for engineering 2D/3D human heart tissues, instruments and hardware for automation, and software packages. Products include hvCM differentiation kits, CTS/CAS/COC fabrication kits, CTScreen System, COScreen System, and associated consumables and maintenance media.
2. Contract Research Services: Customized pharmaceutical drug development services, drug discovery, and R&D consultation services related to new disease models and therapeutics. Services include stem cell differentiation, engineered tissue assays, cardiotoxicity screening, disease modeling, and efficacy studies. Timeline varies from 1 to 12 months depending on scope.
3. Disease Modeling Services: Preclinical human-specific electrophysiology, arrhythmia, contractility, and pressure-volume data for specified disease models to help advance therapeutic candidates toward regulatory approval.
4. Gene Therapy Development Support: Supporting gene therapy clinical development through human cardiac models that led to FDA IND approval and Fast Track Designation for clinical trials.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Novoheart engineers bioartificial human heart tissues from human pluripotent stem cells and sells them, along with related instruments, software, and contract research services, to pharmaceutical and biotechnology companies for drug discovery, disease modeling, and cardiotoxicity screening. Its mini-Heart Platform encompasses four engineered tissue formats (hvCMs, hvCTS, hvCAS, hvCOC 'Human Heart-in-a-Jar'), supported by the CTScreen and COScreen hardware instruments with proprietary software, do-it-yourself fabrication kits, and the broader mini-Life Platform linking multiple mini-organs. It also delivers customized drug discovery, disease modeling, and efficacy study services under 1–12 month timelines.

Product overview

Novoheart offers the mini-Heart Platform, a suite of 4 advanced engineered-tissue formats (hvCMs, hvCTS, hvCAS, hvCOC/Heart-in-a-Jar) fabricated from human stem cell-derived cardiomyocytes for assessing specific cardiac functional outputs. The company also provides the broader mini-Life Platform including other mini-organs (liver, immune, vascular, lung, gut, bile). Novoheart's products range from single-cell products (hvCMs) and do-it-yourself tissue fabrication kits to complete turnkey instrument systems (CTScreen, COScreen) with proprietary software. Services include disease modeling, cardiotoxicity screening, and custom drug discovery using these human cardiac tissue models. Data from the platform has successfully led to IND applications and Fast Track Designation from the FDA.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 100% accuracy for negative inotropic effects, 86-100% accuracy for positive inotropic effects, 80-100% for null inotropic effects in blinded Pfizer screening study
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature9 records

Partnerships

Five partnerships are on record, tiered core and secondary.

• PfizercoreStrategic or Co-development PartnerPartnership with Pfizer's Global Safety Pharmacology Unit and Rare Disease Unit. Conducted double-blinded drug screening study using mini-Heart technology with 25 cardioactive compounds. Co-developed first in vitro model of Friedreich's ataxia cardiomyopathy using patient-derived cells, capturing electrical and mechanical defects. Co-published results in 2019.
• AstraZenecacoreStrategic or Co-development PartnerPartnership to co-develop first human mini-Heart model of Heart Failure with preserved Ejection Fraction (HFpEF). Built preclinical human models to understand disease mechanism and predict effects of potential medicines. This collaboration identified a novel therapeutic target that advanced to clinical trials. AstraZeneca provided testimonial for the partnership.
• AmgensecondaryStrategic or Co-development PartnerContract with Amgen in 2018 to develop high-throughput cardiac contractility screening system. Designed and developed 96-well microplate (96-well μCTS) for screening hundreds of drugs using engineered human ventricular Cardiac Tissue Strips. First prototype completed in 2020 with ongoing development of next-generation version for robotic handling.
• Stanford UniversitysecondaryStrategic or Co-development PartnerAcademic collaboration using patented maturation technology for driving maturation of stem cell-derived heart cells without genetic manipulation. Part of ongoing research partnerships for advancing cardiac tissue engineering.
• SardocorcoreStrategic or Co-development PartnerWholly owned subsidiary of Medera Group focused on novel gene and cell therapies for incurable diseases. Sardocor uses Novoheart's mini-Heart data to support gene therapy IND applications. Three ongoing gene therapy clinical trials for HFpEF, HFrEF, and DMD-related Cardiomyopathy. Sardocor provides one-stop platform access to clinical trial expertise and cGMP manufacturing.

Scale indicators8 records

Recent moves2 records

Expansion highlights5 records

Broad incumbents

• InSphero: InSphero offers 3D microtissue organoid platforms across liver, pancreas, and other tissues for drug discovery, a broader portfolio than Novoheart's cardiac-centric offering but serving similar pharma safety/efficacy use cases.
• Emulate: Emulate's organ-on-chip platform spans multiple organs and is used by large pharma for preclinical testing, competing in the same human-relevant in vitro model category as Novoheart with deeper capital and broader pharma penetration.
• Organovo: Organovo develops 3D bioprinted human tissues for preclinical research and drug discovery, overlapping with Novoheart's engineered tissue approach while operating more broadly across tissue types.
• Charles River Laboratories: Charles River is a major preclinical CRO offering cardiac safety assessment and broader drug discovery services, representing the incumbent scale alternative to Novoheart's specialty cardiac platform.

Emerging players

• CytoPlex: CytoPlex is developing human organoid and tissue platforms for preclinical drug testing, with early-stage overlap in cardiac and multi-organ disease modeling relevant to Novoheart's roadmap.

Direct peers

• Ncardia: Ncardia develops iPSC-derived cardiac cell models and assays for preclinical cardiac safety and efficacy testing, directly overlapping Novoheart's hvCM and disease modeling services for pharma drug discovery.
• Axol Bioscience: Axol Bioscience supplies iPSC-derived cardiomyocytes and other human cell types for disease modeling and drug screening, overlapping Novoheart's hvCM product line and serving the same pharma and academic customers.
• Tara Biosystems (a Valo Health company): Tara Biosystems engineered human cardiac tissue models for drug discovery and cardiotoxicity screening, closely paralleling Novoheart's hvCTS and hvCAS assays and pharma co-development model.
• Nanion Technologies: Nanion provides cardiac safety screening instruments (e.g., electrophysiology and contractility platforms) used for cardiotoxicity testing, competing with Novoheart's CTScreen and COScreen instrument systems.

Others

• Medera (parent): Medera is Novoheart's parent holding company and a strategic platform for gene and cell therapies via Sardocor; relevant as the integrated owner that consolidates Novoheart's disease modeling with downstream clinical development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@novoheart
• Facebookfacebook.com/novoheart
• LinkedInlinkedin.com/company/novoheart
• Xx.com/Novoheart

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novoheart Holdings